文献速递治疗药物监测与药物基因组学

唾液用于抗病毒药物TDM的可行性:系统综述与分析

How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis.
PubMed 文献 · Clin Pharmacokinet · 2026-08-05

该系统综述旨在评估唾液替代血浆用于抗病毒药物TDM的可行性。纳入9项同时报告唾液与血浆浓度的研究,仅(缬)阿昔洛韦和法匹拉韦被认为可能可行,莫努匹拉韦和奥司他韦为不明确但可能,奈玛特韦为不明确但不太可能。结论认为现有数据稀缺且不一致,可行性尚无定论,需标准化研究确认。

要点

  • 唾液TDM可行性分级:阿昔洛韦/缬阿昔洛韦和法匹拉韦可能可行。
  • 莫努匹拉韦和奥司他韦不明确但可能;奈玛特韦不明确但不太可能。
  • 临床实测与基于药物性质的预测不一致,提示转运体等因素影响唾液排泄。

核心结论

  • 现有证据不足以确定唾液抗病毒TDM的临床可行性,但初步证据有前景,需稳健标准化研究确认。

研究设计与样本

  • 系统综述,检索MEDLINE、EMBASE、ClinicalTrials.gov、监管网站及会议摘要,纳入9项同时报告唾液与血浆抗病毒浓度的原始研究。
  • 从PubChem和DrugBank提取抗病毒药物理化性质以预测唾液排泄。
  • 可行性分类定义为:可能、可行、不太可能、不明确但可能、不明确但不太可能五级。

主要发现

  • 9项纳入研究中,(缬)阿昔洛韦和法匹拉韦被认为唾液TDM可能可行。
  • 莫努匹拉韦和奥司他韦为不明确但可能;奈玛特韦为不明确但不太可能。
  • 其他纳入抗病毒药物无原始研究,理化性质提示部分药物唾液渗透可行、部分有限。
  • 临床研究结果有时与基于药物性质的渗透预测相矛盾,提示药物转运体等因素可能显著影响唾液排泄。

临床怎么用

  • 目前不推荐常规以唾液替代血浆进行抗病毒TDM,仅(缬)阿昔洛韦和法匹拉韦有初步可行性证据。
  • 临床决策应优先依据血浆/全血TDM,唾液TDM仅限研究场景。

局限性

  • 同时报告唾液和血浆浓度的研究稀缺,数据不一致。
  • 临床研究结果与药物性质预测存在矛盾,机制未明。
  • 可行性分级基于有限证据,结论不确定。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVE: Immunosuppressed patients are susceptible to serious viral infections, often necessitating antiviral prophylaxis and/or treatment. Therapeutic drug monitoring (TDM) has been proposed to optimise drug exposure and clinical outcomes and is typically performed on full blood/plasma samples. Saliva offers a less invasive, patient-friendly approach, and this systematic review aims to assess the feasibility of saliva-based assays for antiviral TDM. METHODS: We conducted a search on MEDLINE, EMBASE and ClinicalTrials.gov databases, governmental regulatory websites and conference abstracts. Primary studies reporting both saliva and plasma concentrations of antivirals used forprophylaxis or treatment of opportunistic viral infections were included. Physicochemical properties of eachantiviral were compiled from PubChem and DrugBank to predict salivary excretion. Feasibility classifications were defined as follows: (1) likely, (2) possible, (3) unlikely, (4) unclear but possible, (5) unclear but unlikely. RESULTS: We included nine studies in our review. (Val)acyclovir and favipiravir were considered possibly feasible for saliva-based TDM, whereas molnupiravir and oseltamivir were unclear but possible. Nirmatrelvir was deemed unclear but unlikely. For other included antivirals, no primary studies were available, however, physicochemical profiles suggest that salivary penetration may be feasible for some agents but limited for others. CONCLUSION: Studies documenting both saliva and plasma concentrations were scarce, and data was inconsistent. Findings from clinical studies sometimes contradicted predictions of penetration based on drug properties, suggesting that other factors, such as drug transporters, may significantly influence the salivary excretion of antivirals. Future robust, standardised investigations are required to confirm the clinical utility of saliva-based TDM. Feasibility is therefore currently inconclusive, but preliminary evidence is promising.

来源:Clin Pharmacokinet,查看原文。版权归原作者所有。

引用

  1. Lai CW, Wenker SAM, Groundwater PW, et al. How Feasible is the Use of Saliva for Antiviral Therapeutic Drug Monitoring? A Systematic Review and Analysis. Clin Pharmacokinet. 2026. PMID: 42554795. doi:10.1007/s40262-026-01675-9

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。